Currax Pharmaceuticals, has received planning approval for its additional manufacturing site for Contrave/Mysimba in the European Union and European Union Economic Areas (EEA).
The novel site will double the production capacity of Contrave in the European region, which will allow the company to cater to the increasing demand of weight management medications following the soar in global obesity levels.
Amidst the soar in demand for GLP-1 agonists for obesity management, there have been a number of supply chain issues, leaving patients with an inconsistent ability to access the medication they need.
To reduce the impacts of such supply chain issues, Currax will enhance the availability of anti-obesity drugs to ensure the continuous availability of weight management therapeutics.
Currax has submitted an application to the US Food & Drug Administration (FDA) for the approval of the additional site, which is scheduled for later this year.
Contrave is an anti-obesity drug that functions through the modulation of the reward system, and is designed to reduce hunger and control food cravings. It has been available in the US and Europe for more than a decade and has been proven to be be both safe and effective in patients with obesity.
“According to the World Health Organization (WHO), one in eight people are living with obesity and we believe those patients deserve consistent access to medications to treat their disease,” said George Hampton, President and CEO of Currax Pharmaceuticals.
“Access to medications is one of our core values and reliability of supply is a critical component to access. We continue to invest heavily in our ability to supply the unprecedented increase in worldwide demand. This is especially important at a time when the GLP-1 companies are plagued with chronic supply issues,” he continued.
